Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics.
Am J Transplant
; 20(7): 1896-1901, 2020 Jul.
Article
in English
| MEDLINE | ID: covidwho-125541
ABSTRACT
The current coronavirus disease 2019 (COVID-19) pandemic requires extra attention for immunocompromised patients, including solid organ transplant recipients. We report on a case of a 35-year-old renal transplant recipient who suffered from a severe COVID-19 pneumonia. The clinical course was complicated by extreme overexposure to the mammalian target of rapamycin inhibitor everolimus, following coadministration of chloroquine and lopinavir/ritonavir therapy. The case is illustrative for dilemmas that transplant professionals may face in the absence of evidence-based COVID-19 therapy and concurrent pressure for exploration of experimental pharmacological treatment options. However, the risk-benefit balance of experimental or off-label therapy may be weighed differently in organ transplant recipients than in otherwise healthy COVID-19 patients, owing to their immunocompromised status and potential drug interactions with immunosuppressive therapy. With this case report, we aimed to achieve increased awareness and improved management of drug-drug interactions associated with the various treatment options for COVID-19 in renal transplant patients.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Kidney Transplantation
/
Coronavirus Infections
/
Transplant Recipients
/
Everolimus
/
Kidney Failure, Chronic
Type of study:
Case report
/
Prognostic study
Topics:
Long Covid
Limits:
Adult
/
Humans
/
Male
Country/Region as subject:
Europa
Language:
English
Journal:
Am J Transplant
Journal subject:
Transplantation
Year:
2020
Document Type:
Article
Affiliation country:
Ajt.15943
Similar
MEDLINE
...
LILACS
LIS